---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-018315"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2022-09-12T23:59:59+00:00"
generated_at: "2026-06-23T11:16:44.024579+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dyne doses first patient in DYNE-251 DMD trial, initiates DYNE-101 DM1 trial, defers FSHD IND

## Summary
- First patient dosed in Phase 1/2 DELIVER trial of DYNE-251 for DMD exon 51 skipping; registrational trial targeting ~46 patients.
- Initiated Phase 1/2 ACHIEVE trial for DYNE-101 in DM1; first patient expected in September 2022; target ~64 adult patients.
- Deferring IND submission for DYNE-301 (FSHD) originally planned for H2 2022; update expected in 2023.
- Cash runway extended through 2024 due to FSHD program deferral, based on existing cash and equivalents.

## SEC filing metadata
- accession: 0000950170-22-018315
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2022-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017022018315/0000950170-22-018315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017022018315/dyn-20220906.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-018315
- JSON: https://secwatch.observer/filing/0000950170-22-018315.json
- Plain text: https://secwatch.observer/filing/0000950170-22-018315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.